Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MNOV vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Captures Overall Composite Edge (36.0 SELL vs 50.2 HOLD), While MNOV Leads 3–2 on Growth & Valuation Pillars

SRZN Overall Winner 6-Pillar Tally: MNOV 3 – 2 SRZN (1 Tie) Matrix Metrics: MNOV 5 – 4 SRZN

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Medicinova, Inc. (MNOV) on higher Unified Composite conviction (36.0/100 SELL vs. 50.2/100 HOLD) after splitting the core matrix 4–5 (led by Growth & Scale, Options & Positioning), while MNOV wins 3–2 across the 6-pillar growth and valuation breakdown. MNOV trades at $1.31 (8.5x Forward P/E, -1232.2% operating margin) versus SRZN at $28.46 (N/M Forward P/E, -485.4% operating margin).

  • Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -1232.2% operating margin) and revenue trajectory (+408.6% vs. +12.4% YoY).
  • Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNOV vs SRZN
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 73% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $30.47 · SMA50: $26.93

6-Pillar Scorecard Institutional Category Breakdown (MNOV 3 – 2 SRZN)

Columns: Metric · MNOV · SRZN
1. Valuation Multiples MNOV
Forward P/E 8.5x N/M
Trailing P/E 8.5x N/M
PEG Ratio N/M N/M
EV / Revenue 42.5x 52.1x
2. Growth & Scale SRZN
Revenue Growth (YoY) +12.4% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) $935,717 $11M
Market Cap $65.1M $642.7M
3. Profitability & Quality MNOV
Gross Margin 42.2% N/A
Operating Margin -1232.2% -485.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -24.8% -62.8%
4. Balance Sheet & Cash Flow MNOV
Cash Generation (TTM) -$9.1M -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $25M Net Cash $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 140.1% (50th %ile) 72.0% (13th %ile)
Put/Call OI Skew N/A 21.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNOV (5) vs SRZN (4)
Institutional Metric MNOV SRZN Criterion Row Edge
Market Capitalization
Scale
$65.1M $642.7M Larger Scale SRZN
Trailing P/E Ratio
Valuation
8.5x N/M Lower Multiple MNOV
Forward P/E Ratio
Valuation
8.5x N/M Lower Multiple MNOV
Revenue Growth (YoY)
Growth
+12.4% +408.6% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-1232.2% -485.4% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-24.8% -62.8% Higher ROE MNOV
52-Week Range Position
Momentum
3% ($1–$4) 63% ($13–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
0.59β · 38% Vol 1.29β · 73% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite MNOV
Trailing 12M Revenue (USD)
Operating Scale
$935,717 $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 42.5x EV/Rev N/M PEG · 52.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($25M Net Cash) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +17.61 pp
MNOV: -7.09% · SRZN: +10.52%
3M Horizon SRZN +33.11 pp
MNOV: -14.38% · SRZN: +18.73%
6M Horizon SRZN +14.36 pp
MNOV: -6.43% · SRZN: +7.93%
1Y Horizon SRZN +119.2 pp
MNOV: -8.39% · SRZN: +110.81%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MNOV Revenue SRZN Revenue MNOV Op. Margin SRZN Op. Margin Margin Leader
FY2012 $0M N/A -1363.8% N/A MNOV
FY2021 $0M N/A -253.0% N/A MNOV
FY2022 N/A $10M N/A -354.7% SRZN
FY2023 $0M N/A -990.0% N/A MNOV
FY2024 N/A $10M N/A -239.7% SRZN
FY2025 $0M $0M -3242.5% -1210.6% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
41d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 13th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MNOV vs SRZN Key Questions & Quantitative Answers

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Medicinova, Inc. (MNOV) on higher Unified Composite conviction (36.0/100 SELL vs. 50.2/100 HOLD) after splitting the core matrix 4–5 (led by Growth & Scale, Options & Positioning), while MNOV wins 3–2 across the 6-pillar growth and valuation breakdown. MNOV trades at $1.31 (8.5x Forward P/E, -1232.2% operating margin) versus SRZN at $28.46 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -1232.2% operating margin) and revenue trajectory (+408.6% vs. +12.4% YoY). Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: MNOV posts +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 6-period historical trajectory (FY2012 to FY2025), MNOV cumulative revenue shifted N/A while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, MNOV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

MNOV screens cheaper on headline valuation multiples. MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNOV (-24.8% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.